Analysis of the efficacy of capmatinib in non-small cell lung cancer

Capmatinib (Capmatinib) is an innovative drug specifically targeted at the treatment of adult non-small cell lung cancer (NSCLC), especially when the cancer has entered an advanced stage and the cells have specific gene mutations, namely "mesenchymal-epithelial transition factor gene exon 14 (METex-14) skipping." Such mutations cause cancer cells to produce abnormal MET proteins because part of exon 14 of the MET gene is skipped and unused. Capmatinib has become an important treatment option for patients who require further treatment after receiving immunotherapy or platinum-based chemotherapy, or a combination of both.

To further explore the efficacy of capmatinib, a pivotal study included100 patients with advanced NSCLC with a "METex14-skipping" mutation whose disease had progressed despite previous immunotherapy, possibly in combination with platinum-based chemotherapy. Body scans were used to evaluate treatment response, that is, the shrinkage of cancer lesions. The results showed that 44% of patients had partial or complete shrinkage of cancer lesions after receiving capmatinib treatment. It is worth mentioning that this good treatment response lasted for at least 10 months on average. However, the study did not compare capmatinib with other NSCLC treatments or placebo.

MET protein is a member of the receptor tyrosine kinase enzyme family, which plays a key role in cell growth. However, in patients with "METex14 skipped" non-small cell lung cancer, a mutated version of the MET protein is produced, which causes cancer cells to divide and grow uncontrollably. The active ingredient in capmatinib, capmatinib, is a receptor tyrosine kinase inhibitor that can effectively bind to these abnormal MET proteins, thereby blocking the action of MET, thus helping to slow down the growth and spread of cancer.